ELMED Life Sciences Secures $2.7M Series A to Expand Microbiome-Based Healthcare Solutions
Key Insights
ELMED Life Sciences (search) raised $2.7 million in Series A funding from NABVENTURES (search)-managed AgriSURE Fund (search) to advance probiotic and biological solutions across multiple health sectors.
The Hyderabad-based biotech company develops microbiome (search)-based products for animal health, agriculture, aquaculture, and human health, currently exporting to over 18 countries.
Funding will support expanded manufacturing capacity in Hyderabad, strengthen R&D capabilities, and scale distribution in domestic tier 2-3 markets and international regions including Europe, Asia, and Latin America.
Hyderabad-based biotech startup ELMED Life Sciences (search) has secured $2.7 million in Series A funding from the AgriSURE Fund (search), managed by NABVENTURES (search), marking a significant milestone for the company's expansion of microbiome (search)-based healthcare solutions across multiple sectors.
The funding round will enable ELMED to expand its manufacturing operations in Hyderabad, strengthen its research and development capabilities, and scale distribution across domestic and international markets. Founded in 2018 by Pruthivin Reddy Madduri and co-founder Nikhil Konkathi, the company develops probiotic and biological solutions spanning animal health, agriculture, aquaculture, and human health sectors.
Diversified Product Portfolio and Market Approach
ELMED Life Sciences (search) operates through a business-to-business model, serving enterprise clients across multiple sectors with its microbiome (search)-based solutions. The company's farm products focus on improving productivity, immunity, and sustainability, addressing the growing demand for antibiotic-free and sustainable alternatives in agriculture and animal health.
In the human health segment, ELMED partners with pharmaceutical companies including Alchem (search) and Hetero, handling end-to-end formulation and supply for probiotic supplements (search). "We handle end-to-end formulation and supply to pharma companies such as Alchem and Hetero for their probiotic supplements," said founder Pruthivin Reddy Madduri. "We are the manufacturer, while the final product is sold and marketed under our partners' brand names."
The company also serves multinational clients such as Aurobindo (search) and Apex Laboratories (search), demonstrating its established presence in the pharmaceutical manufacturing ecosystem.
Global Expansion Strategy
ELMED currently exports to more than 18 countries and plans to expand its international presence across Europe, Asia, and Latin America. This expansion strategy aligns with rising global demand for sustainable, antibiotic-free solutions in healthcare and agriculture sectors.
Domestically, the company aims to deepen its distribution network in tier 2 and tier 3 markets, where demand for biological solutions is increasing as Indian agriculture moves toward more sustainable and residue-free practices.
Investment Context and Market Opportunity
The funding comes amid broader government support for biotechnology innovation, including the BIRAC (search)-RDI fund (Biotechnology Industry Research Assistance Council–Research, Development and Innovation Fund) launched in February, which allocated Rs 2,000 crore under the government's Rs 1 lakh crore RDI scheme.
"Indian agriculture is steadily moving towards more sustainable and residue-free practices, creating a strong need for reliable biological solutions. Through the AgriSURE Fund (search), we focus on backing businesses that can drive this shift at scale," said Ashish Choudhary, investment manager at AgriSURE Fund, NABVENTURES (search).
The company's diversified approach across animal health, agriculture, aquaculture, and human health positions it to capitalize on the growing global shift toward microbiome (search)-based therapeutic and agricultural solutions, with particular emphasis on sustainability and antibiotic-free alternatives.